drugset / Trial / NCT00953329

Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy

NCT00953329

Phase 4 Terminated 1 enrolled John Murray Astellas Pharma US, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Study Status: Duke University Health System Institutional Review Board has received notification of study termination; final IRB closure date is 12/12/2008. Study enrollment is now closed. Enrollment Update: Only one subject was entered into this study out of an expected enrollment of 15 patients in this single site clinical trial. With no recruitment interest, the financial sponsor and Sponsor-PI chose to close the clinical trial.

Timeline

Start
2008-02
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intramuscular

Indications